Trump Media and Technology Group Corp vs Zimmer Biomet Holdings Inc — how do they compare? Trump Media and Technology Group Corp trades at $9.25 (market cap $2.50B), while Zimmer Biomet Holdings Inc trades at $90.82 (market cap $17.61B). The key difference: Zimmer Biomet Holdings Inc is far larger — about 7× Trump Media and Technology Group Corp's market cap, and Zimmer Biomet Holdings Inc pays a 1.05% dividend while Trump Media and Technology Group Corp pays none. Which is the better fit depends on your goals.
| DJT | ZBH | |
|---|---|---|
Market Cap | $2.50B | $17.61B |
Sector | Media | Health |
52-Week High | $19.86 | $107.71 |
52-Week Low | $7.06 | $79.58 |
Enterprise Value | $2.45B | $24.66B |
Dividend Yield | — | 1.05% |
Signals from Pluang's Aura AI — not financial advice
DJT trades at $8.52, down 0.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported minimal revenue of $3.68M in 2025 alongside a massive net loss of -$712.06M, reflecting severe profitability challenges. Recent news highlights a nearly 50% stock decline in 2026 and the cancellation of a Truth Social spin-off, while a merger with TAE Technologies aims to pivot toward nuclear fusion energy.
The outlook remains highly speculative, with the stock's meme-driven volatility and fundamental weaknesses posing significant risks. Investment opportunity hinges on successful execution of the TAE merger and fusion technology prospects, but persistent losses and high valuation ratios suggest substantial downside potential if growth fails to materialize.
Zimmer Biomet (ZBH) trades at $94.08, up 3.0% in the past 24 hours, near its consensus price target of $97.67. The stock shows bullish technical signals with strong moving average support and has consistently beaten earnings estimates in recent quarters. Revenue grew to $8.23B in 2025, though net income margin declined to 8.56%. Recent corporate developments include expansion in Asia Pacific and a planned $1 billion share repurchase program in 2026.
ZBH presents a balanced outlook with steady revenue growth and shareholder returns via dividends and buybacks, but faces risks from margin compression and rising debt. Analyst sentiment is mixed with 40% buy ratings, suggesting moderate upside potential with caution around profitability trends and competitive pressures in the medical device sector.
Trailing returns across standard periods
Latest headlines on both assets
Trump Media & Technology Group is a media firm rooted in social media and digital streaming. Its flagship product, Truth Social, provides a platform focused on free speech and open conversation.
Read more on DJT →Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →